<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>51</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>3</volume><submitter>Sano T</submitter><pubmed_abstract>MicroRNAs (miRNAs) are short, noncoding RNAs that function as posttranscriptional regulators of gene expression by controlling translation of mRNAs. A subset of miRNAs may be critical for the control of cell death, including the p53-regulated miRNA, miR-34a. Because seizures activate p53, and p53-deficient mice are reportedly resistant to damage caused by prolonged seizures, we investigated the role of miR-34a in seizure-induced neuronal death in vivo. Status epilepticus was induced by intra-amygdala microinjection of kainic acid in mice. This led to an early (2 h) multifold upregulation of miR-34a in the CA3 and CA1 hippocampal subfields and lower protein levels of mitogen-activated kinase kinase kinase 9, a validated miR-34a target. Immunoprecipitation of the RNA-induced silencing complex component, Argonaute-2, eluted significantly higher levels of miR-34a after seizures. Injection of mice with pifithrin-α, a putative p53 inhibitor, prevented miR-34a upregulation after seizures. Intracerebroventricular injection of antagomirs targeting miR-34a reduced hippocampal miR-34a levels and had a small modulatory effect on apoptosis-associated signaling, but did not prevent hippocampal neuronal death in models of either severe or moderate severity status epilepticus. Thus, prolonged seizures cause subfield-specific, temporally restricted upregulation of miR-34a, which may be p53 dependent, but miR-34a is probably not important for seizure-induced neuronal death in this model.</pubmed_abstract><journal>Cell death &amp; disease</journal><pagination>e287</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3317348</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>MicroRNA-34a upregulation during seizure-induced neuronal death.</pubmed_title><pmcid>PMC3317348</pmcid><pubmed_authors>Taki W</pubmed_authors><pubmed_authors>Jimenez-Mateos EM</pubmed_authors><pubmed_authors>Henshall DC</pubmed_authors><pubmed_authors>Reynolds JP</pubmed_authors><pubmed_authors>Matsushima S</pubmed_authors><pubmed_authors>Sano T</pubmed_authors><view_count>51</view_count></additional><is_claimable>false</is_claimable><name>MicroRNA-34a upregulation during seizure-induced neuronal death.</name><description>MicroRNAs (miRNAs) are short, noncoding RNAs that function as posttranscriptional regulators of gene expression by controlling translation of mRNAs. A subset of miRNAs may be critical for the control of cell death, including the p53-regulated miRNA, miR-34a. Because seizures activate p53, and p53-deficient mice are reportedly resistant to damage caused by prolonged seizures, we investigated the role of miR-34a in seizure-induced neuronal death in vivo. Status epilepticus was induced by intra-amygdala microinjection of kainic acid in mice. This led to an early (2 h) multifold upregulation of miR-34a in the CA3 and CA1 hippocampal subfields and lower protein levels of mitogen-activated kinase kinase kinase 9, a validated miR-34a target. Immunoprecipitation of the RNA-induced silencing complex component, Argonaute-2, eluted significantly higher levels of miR-34a after seizures. Injection of mice with pifithrin-α, a putative p53 inhibitor, prevented miR-34a upregulation after seizures. Intracerebroventricular injection of antagomirs targeting miR-34a reduced hippocampal miR-34a levels and had a small modulatory effect on apoptosis-associated signaling, but did not prevent hippocampal neuronal death in models of either severe or moderate severity status epilepticus. Thus, prolonged seizures cause subfield-specific, temporally restricted upregulation of miR-34a, which may be p53 dependent, but miR-34a is probably not important for seizure-induced neuronal death in this model.</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Mar</publication><modification>2024-11-07T00:10:29.575Z</modification><creation>2019-03-27T00:51:51Z</creation></dates><accession>S-EPMC3317348</accession><cross_references><pubmed>22436728</pubmed><doi>10.1038/cddis.2012.23</doi></cross_references></HashMap>